Chapter 5 144 no insomnia, 30% reports mild insomnia, 6.3% reports moderate insomnia and no participant reports severe insomnia. Table 5.2. Baseline demographic characteristics of the participants. Trans men (n=262) Trans women (n=183) Age (years; median (IQR)) 23.2 (20.4; 29.5) 27.5 (22.8; 36.6) BMI (kg/m2; median (IQR)) 24.1 (20.8; 28.4) 22.4 (19.4; 26.8) Alcohol (n, %) Never drinker 100 (38.2%) 69 (37.7%) 1 to 7 drinks per week 112 (42.7%) 75 (41.0%) 7+ drinks per week 10 (3.8%) 8 (4.4%) Missing 40 (15.3%) 31 (16.9%) Drug use (n, %) No drug use 223 (85.1%) 154 (84.1%) Cannabis use 26 (9.9%) 15 (8.2%) Hard drug use 0 (0%) 3 (1.6%) Missing 13 (5.0%) 11 (6.0%) Smoking (n, %) Never 118 (45.0%) 87 (47.5%) Previous 48 (18.3%) 34 (18.6%) Current 63 (24.0%) 36 (19.7%) Missing 32 (12.2%) 26 (14.2%) Psychotropic medication use a. (n, %) Antidepressants 27 (10.3%) 17 (9.3%) Sedative medication 6 (2.3%) 7 (3.8%) Stimulants 5 (1.9%) 6 (3.3%) Antipsychotics 5 (1.9%) 2 (1.1%) Mood stabilizers 0 (0%) 0 (0%) Testosterone form prescribed at start GAHT (n, %) b. - Testosterone gel 69 (26.3%) - Testosterone esters 17 (6.5%) - Testosterone undecanoate 176 (67.2%) - Cycle regulation use at start GAHT (n, %) - Yes 28 (10.7%) - Estrogen form prescribed at start GAHT (n, %) b. Estradiol valerate tablets - 132 (72.1%) Estradiol gel - 18 (9.8%) Estradiol patches - 33 (18.0%) Antiandrogen form prescribed at start GAHT (n, %) b. - Cyproterone acetate - 151 (82.5%) GnRH analogues (short-acting) - 29 (15.8%) GnRH analogues (long-acting) - 0 (0%) Spironolactone 3 (1.6%) a. A single participant could use more than one form of medication at the same time and can therefore be counted multiple times. b. Participants could switch the administration form and dosage of GAHT during the study period. IQR = InterQuartile Range.
RkJQdWJsaXNoZXIy MTk4NDMw